Report cover image

Global Direct Oral Anticoagulants (DOACs) Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 190 Pages
SKU # APRC20279706

Description

Summary

According to APO Research, the global Direct Oral Anticoagulants (DOACs) market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Direct Oral Anticoagulants (DOACs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Direct Oral Anticoagulants (DOACs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Direct Oral Anticoagulants (DOACs) market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Direct Oral Anticoagulants (DOACs) is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Direct Oral Anticoagulants (DOACs) market include Accord Healthcare, Apotex, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Janssen Pharmaceuticals, Teva Pharmaceutical and Viatris, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Direct Oral Anticoagulants (DOACs), sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Direct Oral Anticoagulants (DOACs), also provides the sales of main regions and countries. Of the upcoming market potential for Direct Oral Anticoagulants (DOACs), and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Direct Oral Anticoagulants (DOACs) sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Direct Oral Anticoagulants (DOACs) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Direct Oral Anticoagulants (DOACs) sales, projected growth trends, production technology, application and end-user industry.

Direct Oral Anticoagulants (DOACs) Segment by Company

Accord Healthcare
Apotex
Boehringer Ingelheim
Bristol Myers Squibb
Daiichi Sankyo
GlaxoSmithKline
Janssen Pharmaceuticals
Teva Pharmaceutical
Viatris
Bayer
Pfizer
Mylan
Sandoz
Direct Oral Anticoagulants (DOACs) Segment by Type

Oral Factor Xa Inhibitors
Direct Thrombin Inhibitors (DTIs)
Direct Oral Anticoagulants (DOACs) Segment by Application

Pulmonary Embolism
Deep Vein Thrombosis
Atrial Fibrillation
Other
Direct Oral Anticoagulants (DOACs) Segment by Region

North America

United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global Direct Oral Anticoagulants (DOACs) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Direct Oral Anticoagulants (DOACs) market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Direct Oral Anticoagulants (DOACs) significant trends, drivers, influence factors in global and regions.
6. To analyze Direct Oral Anticoagulants (DOACs) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Direct Oral Anticoagulants (DOACs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Direct Oral Anticoagulants (DOACs) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Direct Oral Anticoagulants (DOACs).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Direct Oral Anticoagulants (DOACs) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Direct Oral Anticoagulants (DOACs) industry.
Chapter 3: Detailed analysis of Direct Oral Anticoagulants (DOACs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Direct Oral Anticoagulants (DOACs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Direct Oral Anticoagulants (DOACs) in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

190 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Direct Oral Anticoagulants (DOACs) Sales Value (2020-2031)
1.2.2 Global Direct Oral Anticoagulants (DOACs) Sales Volume (2020-2031)
1.2.3 Global Direct Oral Anticoagulants (DOACs) Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Direct Oral Anticoagulants (DOACs) Market Dynamics
2.1 Direct Oral Anticoagulants (DOACs) Industry Trends
2.2 Direct Oral Anticoagulants (DOACs) Industry Drivers
2.3 Direct Oral Anticoagulants (DOACs) Industry Opportunities and Challenges
2.4 Direct Oral Anticoagulants (DOACs) Industry Restraints
3 Direct Oral Anticoagulants (DOACs) Market by Company
3.1 Global Direct Oral Anticoagulants (DOACs) Company Revenue Ranking in 2024
3.2 Global Direct Oral Anticoagulants (DOACs) Revenue by Company (2020-2025)
3.3 Global Direct Oral Anticoagulants (DOACs) Sales Volume by Company (2020-2025)
3.4 Global Direct Oral Anticoagulants (DOACs) Average Price by Company (2020-2025)
3.5 Global Direct Oral Anticoagulants (DOACs) Company Ranking (2023-2025)
3.6 Global Direct Oral Anticoagulants (DOACs) Company Manufacturing Base and Headquarters
3.7 Global Direct Oral Anticoagulants (DOACs) Company Product Type and Application
3.8 Global Direct Oral Anticoagulants (DOACs) Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Direct Oral Anticoagulants (DOACs) Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Direct Oral Anticoagulants (DOACs) Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Direct Oral Anticoagulants (DOACs) Market by Type
4.1 Direct Oral Anticoagulants (DOACs) Type Introduction
4.1.1 Oral Factor Xa Inhibitors
4.1.2 Direct Thrombin Inhibitors (DTIs)
4.2 Global Direct Oral Anticoagulants (DOACs) Sales Volume by Type
4.2.1 Global Direct Oral Anticoagulants (DOACs) Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Direct Oral Anticoagulants (DOACs) Sales Volume by Type (2020-2031)
4.2.3 Global Direct Oral Anticoagulants (DOACs) Sales Volume Share by Type (2020-2031)
4.3 Global Direct Oral Anticoagulants (DOACs) Sales Value by Type
4.3.1 Global Direct Oral Anticoagulants (DOACs) Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Direct Oral Anticoagulants (DOACs) Sales Value by Type (2020-2031)
4.3.3 Global Direct Oral Anticoagulants (DOACs) Sales Value Share by Type (2020-2031)
5 Direct Oral Anticoagulants (DOACs) Market by Application
5.1 Direct Oral Anticoagulants (DOACs) Application Introduction
5.1.1 Pulmonary Embolism
5.1.2 Deep Vein Thrombosis
5.1.3 Atrial Fibrillation
5.1.4 Other
5.2 Global Direct Oral Anticoagulants (DOACs) Sales Volume by Application
5.2.1 Global Direct Oral Anticoagulants (DOACs) Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Direct Oral Anticoagulants (DOACs) Sales Volume by Application (2020-2031)
5.2.3 Global Direct Oral Anticoagulants (DOACs) Sales Volume Share by Application (2020-2031)
5.3 Global Direct Oral Anticoagulants (DOACs) Sales Value by Application
5.3.1 Global Direct Oral Anticoagulants (DOACs) Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Direct Oral Anticoagulants (DOACs) Sales Value by Application (2020-2031)
5.3.3 Global Direct Oral Anticoagulants (DOACs) Sales Value Share by Application (2020-2031)
6 Direct Oral Anticoagulants (DOACs) Regional Sales and Value Analysis
6.1 Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Direct Oral Anticoagulants (DOACs) Sales by Region (2020-2031)
6.2.1 Global Direct Oral Anticoagulants (DOACs) Sales by Region: 2020-2025
6.2.2 Global Direct Oral Anticoagulants (DOACs) Sales by Region (2026-2031)
6.3 Global Direct Oral Anticoagulants (DOACs) Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Direct Oral Anticoagulants (DOACs) Sales Value by Region (2020-2031)
6.4.1 Global Direct Oral Anticoagulants (DOACs) Sales Value by Region: 2020-2025
6.4.2 Global Direct Oral Anticoagulants (DOACs) Sales Value by Region (2026-2031)
6.5 Global Direct Oral Anticoagulants (DOACs) Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Direct Oral Anticoagulants (DOACs) Sales Value (2020-2031)
6.6.2 North America Direct Oral Anticoagulants (DOACs) Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Direct Oral Anticoagulants (DOACs) Sales Value (2020-2031)
6.7.2 Europe Direct Oral Anticoagulants (DOACs) Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Value (2020-2031)
6.8.2 Asia-Pacific Direct Oral Anticoagulants (DOACs) Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Direct Oral Anticoagulants (DOACs) Sales Value (2020-2031)
6.9.2 South America Direct Oral Anticoagulants (DOACs) Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales Value (2020-2031)
6.10.2 Middle East & Africa Direct Oral Anticoagulants (DOACs) Sales Value Share by Country, 2024 VS 2031
7 Direct Oral Anticoagulants (DOACs) Country-level Sales and Value Analysis
7.1 Global Direct Oral Anticoagulants (DOACs) Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Direct Oral Anticoagulants (DOACs) Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Direct Oral Anticoagulants (DOACs) Sales by Country (2020-2031)
7.3.1 Global Direct Oral Anticoagulants (DOACs) Sales by Country (2020-2025)
7.3.2 Global Direct Oral Anticoagulants (DOACs) Sales by Country (2026-2031)
7.4 Global Direct Oral Anticoagulants (DOACs) Sales Value by Country (2020-2031)
7.4.1 Global Direct Oral Anticoagulants (DOACs) Sales Value by Country (2020-2025)
7.4.2 Global Direct Oral Anticoagulants (DOACs) Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.5.2 USA Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.6.2 Canada Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.8.2 Germany Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.9.2 France Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.9.3 France Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.11.2 Italy Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.12.2 Spain Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.13.2 Russia Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.16.2 China Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.16.3 China Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.17.2 Japan Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.19.2 India Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.19.3 India Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.20.2 Australia Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.24.2 Chile Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.26.2 Peru Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.28.2 Israel Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.29.2 UAE Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.31.2 Iran Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Direct Oral Anticoagulants (DOACs) Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Direct Oral Anticoagulants (DOACs) Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Direct Oral Anticoagulants (DOACs) Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Accord Healthcare
8.1.1 Accord Healthcare Comapny Information
8.1.2 Accord Healthcare Business Overview
8.1.3 Accord Healthcare Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2020-2025)
8.1.4 Accord Healthcare Direct Oral Anticoagulants (DOACs) Product Portfolio
8.1.5 Accord Healthcare Recent Developments
8.2 Apotex
8.2.1 Apotex Comapny Information
8.2.2 Apotex Business Overview
8.2.3 Apotex Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2020-2025)
8.2.4 Apotex Direct Oral Anticoagulants (DOACs) Product Portfolio
8.2.5 Apotex Recent Developments
8.3 Boehringer Ingelheim
8.3.1 Boehringer Ingelheim Comapny Information
8.3.2 Boehringer Ingelheim Business Overview
8.3.3 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2020-2025)
8.3.4 Boehringer Ingelheim Direct Oral Anticoagulants (DOACs) Product Portfolio
8.3.5 Boehringer Ingelheim Recent Developments
8.4 Bristol Myers Squibb
8.4.1 Bristol Myers Squibb Comapny Information
8.4.2 Bristol Myers Squibb Business Overview
8.4.3 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2020-2025)
8.4.4 Bristol Myers Squibb Direct Oral Anticoagulants (DOACs) Product Portfolio
8.4.5 Bristol Myers Squibb Recent Developments
8.5 Daiichi Sankyo
8.5.1 Daiichi Sankyo Comapny Information
8.5.2 Daiichi Sankyo Business Overview
8.5.3 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2020-2025)
8.5.4 Daiichi Sankyo Direct Oral Anticoagulants (DOACs) Product Portfolio
8.5.5 Daiichi Sankyo Recent Developments
8.6 GlaxoSmithKline
8.6.1 GlaxoSmithKline Comapny Information
8.6.2 GlaxoSmithKline Business Overview
8.6.3 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2020-2025)
8.6.4 GlaxoSmithKline Direct Oral Anticoagulants (DOACs) Product Portfolio
8.6.5 GlaxoSmithKline Recent Developments
8.7 Janssen Pharmaceuticals
8.7.1 Janssen Pharmaceuticals Comapny Information
8.7.2 Janssen Pharmaceuticals Business Overview
8.7.3 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2020-2025)
8.7.4 Janssen Pharmaceuticals Direct Oral Anticoagulants (DOACs) Product Portfolio
8.7.5 Janssen Pharmaceuticals Recent Developments
8.8 Teva Pharmaceutical
8.8.1 Teva Pharmaceutical Comapny Information
8.8.2 Teva Pharmaceutical Business Overview
8.8.3 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2020-2025)
8.8.4 Teva Pharmaceutical Direct Oral Anticoagulants (DOACs) Product Portfolio
8.8.5 Teva Pharmaceutical Recent Developments
8.9 Viatris
8.9.1 Viatris Comapny Information
8.9.2 Viatris Business Overview
8.9.3 Viatris Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2020-2025)
8.9.4 Viatris Direct Oral Anticoagulants (DOACs) Product Portfolio
8.9.5 Viatris Recent Developments
8.10 Bayer
8.10.1 Bayer Comapny Information
8.10.2 Bayer Business Overview
8.10.3 Bayer Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2020-2025)
8.10.4 Bayer Direct Oral Anticoagulants (DOACs) Product Portfolio
8.10.5 Bayer Recent Developments
8.11 Pfizer
8.11.1 Pfizer Comapny Information
8.11.2 Pfizer Business Overview
8.11.3 Pfizer Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2020-2025)
8.11.4 Pfizer Direct Oral Anticoagulants (DOACs) Product Portfolio
8.11.5 Pfizer Recent Developments
8.12 Mylan
8.12.1 Mylan Comapny Information
8.12.2 Mylan Business Overview
8.12.3 Mylan Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2020-2025)
8.12.4 Mylan Direct Oral Anticoagulants (DOACs) Product Portfolio
8.12.5 Mylan Recent Developments
8.13 Sandoz
8.13.1 Sandoz Comapny Information
8.13.2 Sandoz Business Overview
8.13.3 Sandoz Direct Oral Anticoagulants (DOACs) Sales, Value and Gross Margin (2020-2025)
8.13.4 Sandoz Direct Oral Anticoagulants (DOACs) Product Portfolio
8.13.5 Sandoz Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Direct Oral Anticoagulants (DOACs) Value Chain Analysis
9.1.1 Direct Oral Anticoagulants (DOACs) Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Direct Oral Anticoagulants (DOACs) Sales Mode & Process
9.2 Direct Oral Anticoagulants (DOACs) Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Direct Oral Anticoagulants (DOACs) Distributors
9.2.3 Direct Oral Anticoagulants (DOACs) Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.